Covid-fat­tened shares crash as FDA puts a late-stage coro­n­avirus vac­cine tri­al on hold

Af­ter see­ing its mar­ket cap soar on the prospects of a high­ly-tout­ed Covid-19 vac­cine, In­ovio saw its share price $INO led to slaugh­ter on Mon­day af­ter an­nounc­ing that the FDA is forc­ing in­ves­ti­ga­tors to hit the brakes on a planned Phase II/III study.

The agency has some ques­tions for In­ovio right now, in­clud­ing queries re­lat­ed to “its Cel­lec­tra 2000 de­liv­ery de­vice to be used in the tri­al.” But In­ovio’s state­ment al­so didn’t spell out what the holdup was about, leav­ing con­sid­er­able un­cer­tain­ty about the fate of INO-4800:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER